An international consensus panel has called for the disease to be renamed from non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD) and has suggested how the disease should be diagnosed. This Viewpoint explores the call from the perspective of patient ...
Fatty liver is the accumulation of triglycerides and other fats in the liver cells. The amount of fatty acid in the liver depends on the balance between the processes of delivery and removal. In some patients, fatty liver may be accompanied by hepatic inflammation and liver cell death (steatohe...
Treating the patient with nonalcoholic fatty liver diseasedoi:10.1097/01.NPR.0000473350.94522.56NoneThe Nurse PractitionerA. Chaney, "Treating the patient with nonalcoholic fatty liver disease," The Nurse Practitioner, vol. 40, no. 11, pp. 36-42, 2015....
The purpose of this patient guideline This guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is a serious condition. It is important that you develop a full understanding of it. This has several advantages: first, it enables ...
Sample types and patient preparation required when adopting the new fatty liver disease nomenclature doi:10.1016/j.jhep.2023.07.030Journal of Hepatology, with SupplementsKate Elizabeth Shipman
1. They might evenblame youfor your condition.When it comes to fatty liver, diabetes, heart problems, and weight issues, many doctorsblame the patient, saying they have no self-control or they don’t exercise enough. The fact is though, most doctors refuse to admit howtoxicour world has ...
et al. Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient. J. Korean Med. Sci. 20, 150–152 (2005). PubMed PubMed Central Google Scholar Aldersley, M. A. & Howdle, P. D. Intestinal permeability and liver disease....
et al. Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide. Hepatology 52, 105–114 (2010). Article CAS PubMed Google Scholar Augoustides-Savvopoulou, P. et al. Glycine N-methyltransferase deficiency: a new patient with a novel mutation. J....
doi:10.1371/journal.pone.0140908PubMedGoogle ScholarCrossref My Doctor Told Me I Have Fatty Liver—What Do I Need to Know? JAMA Internal Medicine JAMA Internal Medicine Patient Page September 1, 2019 This Patient Page describes nonalcoholic fatty liver disease and strategies for its treatment. ...
Recompensation has gained increasing attention in the field of cirrhosis, particularly in chronic liver disease with a definite aetiology. The current global prevalence of obesity and nonalcoholic fatty liver disease (NAFLD) is increasing, but there is currently a lack of a clear definition for re...